| (Values in U.S. Thousands) | Jul, 2025 | Apr, 2025 | Jan, 2025 | Oct, 2024 | Jul, 2024 |
| Sales | 350 | 360 | 80 | 130 | 170 |
| Sales Growth | -2.78% | +350.00% | -38.46% | -23.53% | -50.00% |
| Net Income | -12,090 | -4,780 | -4,640 | -9,010 | -4,470 |
| Net Income Growth | -152.93% | -3.02% | +48.50% | -101.57% | +86.18% |
Rafael Holdings Inc (RFL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Rafael Holdings Inc. manufactures metabolic oncology drugs to treat cancer. The company's product pipeline consists of CPI-613, CPI-618, CPI-1826 and CPI-3220 which are in clinical stages. Rafael Holdings Inc. is based in Newark, United States.
Fiscal Year End Date: 07/31